8.70
-0.16(-1.81%)
Currency In USD
| Previous Close | 8.86 |
| Open | 8.79 |
| Day High | 8.9 |
| Day Low | 8.42 |
| 52-Week High | 9.54 |
| 52-Week Low | 1.78 |
| Volume | 1.05M |
| Average Volume | 2.28M |
| Market Cap | 1.51B |
| PE | -5.06 |
| EPS | -1.72 |
| Moving Average 50 Days | 8.12 |
| Moving Average 200 Days | 5.38 |
| Change | -0.16 |
If you invested $1000 in Relay Therapeutics, Inc. (RLAY) since IPO date, it would be worth $248.22 as of February 21, 2026 at a share price of $8.7. Whereas If you bought $1000 worth of Relay Therapeutics, Inc. (RLAY) shares 5 years ago, it would be worth $197.64 as of February 21, 2026 at a share price of $8.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 10:55 PM GMT
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic dise
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 9:05 PM GMT
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic dise
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
GlobeNewswire Inc.
Feb 03, 2026 12:00 PM GMT
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) i